PT  - JOURNAL ARTICLE
AU  - Emily J. Cox
AU  - Dan-Dan Tian
AU  - John D. Clarke
AU  - Allan E. Rettie
AU  - Jashvant D. Unadkat
AU  - Kenneth E. Thummel
AU  - Jeannine S. McCune
AU  - Mary F. Paine
ED  - Jeong, Hyunyoung
TI  - Modeling Pharmacokinetic Natural Product–Drug Interactions for Decision-Making: A NaPDI Center Recommended Approach
AID  - 10.1124/pharmrev.120.000106
DP  - 2021 Apr 01
TA  - Pharmacological Reviews
PG  - 847--859
VI  - 73
IP  - 2
4099  - http://pharmrev.aspetjournals.org/content/73/2/847.short
4100  - http://pharmrev.aspetjournals.org/content/73/2/847.full
SO  - Pharmacol Rev2021 Apr 01; 73
AB  - The popularity of botanical and other purported medicinal natural products (NPs) continues to grow, especially among patients with chronic illnesses and patients managed on complex prescription drug regimens. With few exceptions, the risk of a given NP to precipitate a clinically significant pharmacokinetic NP-drug interaction (NPDI) remains understudied or unknown. Application of static or dynamic mathematical models to predict and/or simulate NPDIs can provide critical information about the potential clinical significance of these complex interactions. However, methods used to conduct such predictions or simulations are highly variable. Additionally, published reports using mathematical models to interrogate NPDIs are not always sufficiently detailed to ensure reproducibility. Consequently, guidelines are needed to inform the conduct and reporting of these modeling efforts. This recommended approach from the Center of Excellence for Natural Product Drug Interaction Research describes a systematic method for using mathematical models to interpret the interaction risk of NPs as precipitants of potential clinically significant pharmacokinetic NPDIs. A framework for developing and applying pharmacokinetic NPDI models is presented with the aim of promoting accuracy, reproducibility, and generalizability in the literature.Significance Statement Many natural products (NPs) contain phytoconstituents that can increase or decrease systemic or tissue exposure to, and potentially the efficacy of, a pharmaceutical drug; however, no regulatory agency guidelines exist to assist in predicting the risk of these complex interactions. This recommended approach from a multi-institutional consortium designated by National Institutes of Health as the Center of Excellence for Natural Product Drug Interaction Research provides a framework for modeling pharmacokinetic NP-drug interactions.